Project: First-in-class targeted epigenetic therapy for the treatment of Diffuse Large B-cell Lymphoma.
| Acronym | EPIGENEXT (Reference Number: 115574) |
| Duration | 01/09/2021 - 01/09/2024 |
| Project Topic | The consortium will deliver a first-in-class targeted epigenetic therapeutic for diffuse large B-cell lymphoma (DLBCL). Using our proprietary drug development platform, promising chemical series have been identified and hit-to-lead optimisation has been initiated. By project completion, a small molecule-based preclinical candidate will be delivered, supported by preclinical safety and efficacy data. The compound will be ready to enter clinical trials 18 months after project completion (Q1 2026). |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Lead Pharma Holding B.V. | Coordinator | Netherlands |
| 2 | Oxeltis | Partner | France |